These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36189797)

  • 1. Protein vaccine NVX-CoV2373 elicits functional T cell immunity.
    Zhou P
    J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 36189797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
    Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
    J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses.
    Rydyznski Moderbacher C; Kim C; Mateus J; Plested J; Zhu M; Cloney-Clark S; Weiskopf D; Sette A; Fries L; Glenn G; Crotty S
    J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 35943810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
    PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines.
    Sheng WH; Lin PH; Cheng YC; Wu YY; Hsieh MJ; Yang HC; Chang SY; Chang SC
    J Formos Med Assoc; 2024 Mar; 123(3):340-346. PubMed ID: 37996322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
    Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
    Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
    Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
    JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
    Underwood E; Dunkle LM; Madhi SA; Gay CL; Heath PT; Kotloff KL; Smith K; Chau G; Galbiati S; McGarry A; Woo W; Cho I; Alves K; Áñez G; Bennett C; Shinde V; Fries L; Mallory RM; Glenn GM; Toback S
    Expert Rev Vaccines; 2023; 22(1):501-517. PubMed ID: 37246757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM;
    Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
    Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Masuda T; Mori M
    Vaccine; 2024 Feb; 42(6):1319-1325. PubMed ID: 38310018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Kuriyama K; Murakami K; Masuda T; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2023 Jun; 41(25):3763-3771. PubMed ID: 37198021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
    Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
    Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2024 Jan; 42(3):662-670. PubMed ID: 38129286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
    Gorman MJ; Patel N; Guebre-Xabier M; Zhu AL; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yuan D; Bowman KA; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger DA; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
    Cell Rep Med; 2021 Sep; 2(9):100405. PubMed ID: 34485950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
    Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y
    Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
    Bhiman JN; Richardson SI; Lambson BE; Kgagudi P; Mzindle N; Kaldine H; Crowther C; Gray G; Bekker LG; ; Shinde V; Bennett C; Glenn GM; Madhi SA; Moore PL
    Sci Rep; 2023 Jan; 13(1):1222. PubMed ID: 36681693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.